Radioprotective effect of melatonin for hyperthyroidism treatment with iodine-131

Radioprotective effect of melatonin in hyperthyroid patients treated by iodine-131

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014090419045N1

Enrollment

Registered

2014-10-07

Start date

2014-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hyperthyroidism. Condition 2: Radiation damages. Disorders of thyroid gland Exposure to ionizing radiation

Interventions

Intervention 1: Administration of a capsule containing 300 mg of melatonin powder. Intervention 2: Administration of a capsule containing glucose powder.

Prevention

Placebo

Administration of a capsule containing 300 mg of melatonin powder

Administration of a capsule containing glucose powder

Eligibility

Sex/Gender

Female

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: female; right-handed; blood group: O+; receiving 12 mCi iodine-131 Exclusion criteria: individuals who have genetic disorders ,cancer or chemical injuries; smokers; radiation workers; and patients undergoing chemotherapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Micronuclei frequency. Timepoint: Just before iodine-131 administration; and also 1 hour after that. Method of measurement: Cytokinesis blocked micronuclei assessment.	—

Secondary

Measure	Time frame
Thyroid gland function. Timepoint: Before intervention; and 3 months after. Method of measurement: TSH, T4 and T3 level in blood samples.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoudabe Alidadi

Babol University of Medical Sciences

s.alidadi@mubabol.ac.ir ; soudabealidadi@yahoo.com+98 11 3219 9592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026